Enzon Pharmaceuticals has PEGged its future on researching ways to fight cancer. The company has developed compounds using its PEGylation and Locked Nucleic Acid (LNA) technology platforms to improve the performance and deliverability of existing cancer drugs. PEGylation involves attaching polyethylene glycol (PEG) to a drug compound to make it more effective and less toxic for patients.  However, in 2012 Enzon suspended clinical efforts and began reviewing strategic options; in 2013 it refocused on minimizing expenses and maximizing royalty revenue returns.